[Analysis of outocome of pirarubicin-based combination chemotherapy regimen in the treatment of newly diagnosed acute myeloid leukemia-a prospective, open, randomized and multicenter clinical trial].

Yanyan Wang, Sheng Xiao-mei, Rongyan Zhang, Xiaonan Guo, Hui Sun, Xin Wang, Jinlin Zhang, Junmin Li, Zhixiang ShenPubMed 2010

Abstract

There is no difference of the effect between TA and DA chemotherapy for newly diagnosed AML patients. But for subtype M(2), TA is more efficacy. And there is no difference in side effect between the two regimens.
BibTeX
@inproceedings{wang2010analysis,
  author = {Yanyan Wang and Sheng Xiao-mei and Rongyan Zhang and Xiaonan Guo and Hui Sun and Xin Wang and Jinlin Zhang and Junmin Li and Zhixiang Shen},
  title = {{[Analysis of outocome of pirarubicin-based combination chemotherapy regimen in the treatment of newly diagnosed acute myeloid leukemia-a prospective, open, randomized and multicenter clinical trial].}},
  booktitle = {PubMed},
  year = {2010},
}

Loading related content...

Figure